SUPPORTING INFECTIOUS DISEASE RESEARCH

Acinetobacter baumannii, Strain MRSN 24603

Catalog No. NR-52209

Product Description:

Acinetobacter baumannii (A. baumannii), strain MRSN 24603 was isolated in 2014 from human blood in Europe as part of a global surveillance program. NR-52209 was deposited as multi-locus sequence type (MLST) ST 428, sensitive to amikacin, ampicillin/sulbactam, cefepime, ceftazidime, ciprofloxacin, ceftriaxone, colistin, gentamicin, imipenem, levofloxacin, meropenem, tobramycin, tetracycline and trimethoprim/sulfamethoxazole. NR-52209 was produced by inoculation of BEI Resources seed lot 70042469 into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70056950

Manufacturing Date: 30NOV2022

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: <u>Contact@BEIResources.org</u>. We try to respond to feedback within 24 hours.

| TEST | SPECIFICATIONS | RESULTS |
|--|--|--|
| Phenotypic Analysis | | |
| Cellular morphology | Gram-negative rods | Gram-negative rods |
| Colony morphology | Report results | Circular, convex, entire, smooth and cream (Figure 1) |
| Growth at 44°C ± 2°C ¹ | Growth | Growth |
| 1 day in an aerobic atmosphere on Tryptic Soy agar | | |
| Motility | Report results | Motile |
| Remel [™] Motility Test Medium w/TTC Indicator | Report results | Mone |
| for 1 day at 37°C in an aerobic atmosphere | | |
| VITEK [®] MS (MALDI-TOF) | A. baumannii | A. baumannii (99.9%) |
| Antibiotic Susceptibility Profile ^{2,3} | | |
| Amikacin | Sensitive | Sensitive (2 µg/mL) |
| Ampicillin/sulbactam | Sensitive | Sensitive (0.5 µg/mL) |
| Cefepime | Sensitive | Sensitive (0.75 µg/mL) |
| Ceftriaxone | Sensitive | Sensitive (8 µg/mL) |
| Ceftazidime | Sensitive | Sensitive (2 µg/mL) |
| Ciprofloxacin | Sensitive | Sensitive (≤ 0.25 µg/mL) |
| Gentamicin | Sensitive | Sensitive (≤ 1 µg/mL) |
| Imipenem | Sensitive | Sensitive (0.25 µg/mL) |
| Levofloxacin | Sensitive | Sensitive (≤ 0.12 µg/mL) |
| Meropenem | Sensitive | Sensitive (≤ 0.25 µg/mL) |
| Trimethoprim/sulfamethoxazole | Sensitive | Sensitive (≤ 20 µg/mL) |
| Tobramycin | Sensitive | Sensitive (≤ 1 µg/mL) |
| Tetracycline | Sensitive | Sensitive (2 µg/mL) |
| Genotypic Analysis | | |
| Sequencing of 16S ribosomal RNA gene | ≥ 99% sequence identity to | 99.9% sequence identity to |
| (~ 1440 base pairs) | A. baumannii, strain MRSN 24603 (GenBank: VHGG01000121.1) | <i>A. baumannii</i> , strain MRSN 24603 (GenBank: VHGG01000121.1) |
| Purity | Growth consistent with expected | Growth consistent with expected |
| 7 days at 37°C in an aerobic atmosphere with and without 5% CO ₂ on Tryptic Soy agar | colony morphology | colony morphology |
| Viability | Growth | Growth |

E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898 **b**|**e**|**i** resources

Certificate of Analysis for NR-52209

SUPPORTING INFECTIOUS DISEASE RESEARCH

¹Growth at 44°C differentiates *A. baumannii* from *A. calcoaceticus* and *A. pittii*, which do not grow at 44°C. ²Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018) ³Antibiotic susceptibility was tested using a combination of VITEK[®]2 GN81 and E-test strips.


Figure 1: Colony Morphology



/Sonia Bjorum Brower/ Sonia Bjorum Brower

Technical Manager or designee, ATCC Federal Solutions

ATCC[®], on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC[®]'s knowledge.





14 SEP 2023